消息指出,该新药系和铂医药与四川科伦博泰生物医药共同开发项目,双方在大中华区和部分东南亚、西亚地区享有权利。根据早前与Windward Bio AG的授权协议,和铂医药和科伦博泰有机会获得最高9.7亿美元的预付款及里程碑付款,以及产品净销售额的单双位数百分比特许权使用费。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.